BIO-TECHNE CFO reports 9,980-share award conversion

Restricted stock units were scheduled to vest through August 15, 2028, while portions of performance awards were forfeited.

Available on EDGAR 11/02/2026 - 04:40 PM EST Accepted by SEC EDGAR 11/02/2026 - 04:40 PM EST

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

4/A

Rhea-AI Filing Summary

BIO-TECHNE Corp (TECH) CFO James Hippel reported transactions on August 15, 2026. The transactions included conversion of restricted stock units into 9,980 common shares and 4,423 shares delivered or withheld for payment of exercise price or tax liability at $72.40 per share. The transactions also report forfeiture of 34,443 performance stock options and 12,798 performance RSUs; linked footnotes say the Board authorized discretionary vesting of 2,871 performance options and 1,067 performance RSUs.

Insider Trade Summary

9,980 shares exercised/converted

Exercise 7 txns

Insider Hippel James

Role CFO

Type	Security	Shares	Price	Value
Disposition	Performance Stock Options (Right to Buy) ^F1	34,443	$0.00	$0.00
Exercise	Performance Restricted Stock Units ^{F2, F3}	1,067	$0.00	$0.00
Disposition	Performance Restricted Stock Units ^{F2, F3}	12,798	$0.00	$0.00
Exercise	Restricted Stock Units ^{F2, F4}	4,010	$0.00	$0.00
Exercise	Restricted Stock Units ^{F2, F5}	4,903	$0.00	$0.00
Exercise	Common Stock	9,980	$0.00	$0.00
Exercise Price or Tax Liability	Common Stock	4,423	$72.40	$320K

Holdings After Transaction: Performance Stock Options (Right to Buy) — 2,871 contracts (Direct); Performance Restricted Stock Units — 0 contracts (Direct); Restricted Stock Units — 13,818 contracts (Direct); Common Stock — 170,271 shares (Direct)

Footnotes (5)

F1. On 8/15/2026, the Board of Directors authorized discretionary vesting for 2,871 performance options. The remainder of the performance options were forfeited.
F2. Each restricted stock unit represents a contingent right to receive one share of Bio-Techne Corporation common stock.
F3. On 8/15/2026, the Board of Directors authorized discretionary vesting for 1,067 performance RSUs. The remainder of the performance RSUs were forfeited.
F4. 4,010 restricted stock units vest on 8/15/2026; and 4,011 restricted stock units vest on 8/15/2027.
F5. 4,903 restricted stock units vest on each of 8/15/2026 and 8/15/2027, and 4,904 restricted stock units vest on 8/15/2028.

Key Figures

Common shares acquired through RSU conversion: 9,980 shares Shares delivered or withheld for exercise price or tax liability: 4,423 shares Reported transaction price per share: $72.40 per share +4 more

7 metrics

Common shares acquired through RSU conversion 9,980 shares August 15, 2026

Shares delivered or withheld for exercise price or tax liability 4,423 shares August 15, 2026

Reported transaction price per share $72.40 per share For the 4,423 shares delivered or withheld on August 15, 2026

Performance stock options forfeited 34,443 options August 15, 2026

Performance options authorized for discretionary vesting 2,871 options August 15, 2026

Performance RSUs forfeited 12,798 RSUs August 15, 2026

Performance RSUs authorized for discretionary vesting 1,067 RSUs August 15, 2026

Key Terms

Performance Stock Options (Right to Buy), contingent right, discretionary vesting, exercise price or tax liability

4 terms

Performance Stock Options (Right to Buy) financial

"Performance Stock Options (Right to Buy)"

contingent right financial

"Each restricted stock unit represents a contingent right to receive one share"

discretionary vesting financial

"authorized discretionary vesting for 2,871 performance options"

exercise price or tax liability financial

"payment of exercise price or tax liability by delivering or withholding securities"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What stock transactions did BIO-TECHNE CFO James Hippel report?

James Hippel reported conversion of restricted stock units into 9,980 common shares and 4,423 shares delivered or withheld for payment of exercise price or tax liability at $72.40 per share, along with performance-award forfeitures, on August 15, 2026.

What was the vesting schedule for BIO-TECHNE CFO James Hippel's restricted stock units?

4,010 restricted stock units vest on August 15, 2026, and 4,011 vest on August 15, 2027. Another 4,903 vest on each of August 15, 2026 and August 15, 2027, and 4,904 vest on August 15, 2028.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Hippel James

(Last)

(First)

(Middle)

614 MCKINLEY PLACE NE

(Street)

MINNEAPOLIS

MINNESOTA

55413

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
BIO-TECHNE Corp [ TECH ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	CFO

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/15/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)
08/18/2026

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	08/15/2026		M		9,980	A	$0	174,694	D
Common Stock	08/15/2026		F		4,423	D	$72.4	170,271	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Performance Stock Options (Right to Buy)	$84.61	08/15/2026		D			34,443	⁽¹⁾	⁽¹⁾	Common Stock	34,443	$0	2,871	D
Performance Restricted Stock Units	⁽²⁾	08/15/2026		M			1,067	⁽³⁾	⁽³⁾	Common Stock	1,067	$0	12,798	D
Performance Restricted Stock Units	⁽²⁾	08/15/2026		D			12,798	⁽³⁾	⁽³⁾	Common Stock	12,798	$0	0	D
Restricted Stock Units	⁽²⁾	08/15/2026		M			4,010	⁽⁴⁾	⁽⁴⁾	Common Stock	4,010	$0	4,011	D
Restricted Stock Units	⁽²⁾	08/15/2026		M			4,903	⁽⁵⁾	⁽⁵⁾	Common Stock	4,903	$0	9,807	D

Explanation of Responses:

1. On 8/15/2026, the Board of Directors authorized discretionary vesting for 2,871 performance options. The remainder of the performance options were forfeited.

2. Each restricted stock unit represents a contingent right to receive one share of Bio-Techne Corporation common stock.

3. On 8/15/2026, the Board of Directors authorized discretionary vesting for 1,067 performance RSUs. The remainder of the performance RSUs were forfeited.

4. 4,010 restricted stock units vest on 8/15/2026; and 4,011 restricted stock units vest on 8/15/2027.

5. 4,903 restricted stock units vest on each of 8/15/2026 and 8/15/2027, and 4,904 restricted stock units vest on 8/15/2028.

	/s/ Andrew Nick as Attorney-in-Fact for James Hippel pursuant to Power of Attorney previously filed	11/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR